Clinical Trial Update: Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating idarubicin, cytarabine, and nivolumab in high-risk myelodysplastic syndrome and acute myeloid leukemia; study completed with posted r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Idarubicin (idarubicin)
• nivolumab (nivolumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia, Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-10-07